After 6 months of treatment, the serum IL-18 level in pediatric-onset SLE patients was significantly correlated with SLE global disease activity and the severity of lupus nephritis, suggesting that the NLRP3 inflammasome might modulate SLE treatment through IL-18 (43). The gene discussed is NLRP3; the disease is systemic lupus erythematosus.